Chr. Hansen was re-listed in June 2010 after a 5 year period where the company was controlled by the French private equity company PAI. During the private equity ownership CHR has been transformed from a wide covering feed ingredients company to a focused bioscience company. CHR's products represent only a minor part of customer’s costs but have a material positive impact on their end product - i.e. the cost benefit will underpin the long term relationships.